Literature DB >> 31253663

Atypical haemolytic uremic syndrome from multiple missenses to a full-blown disease.

Filipe Santos Mira1,2, Ana Luísa Nunes3, Ana Rita Elvas3, Nuno Oliveira1,2.   

Abstract

A 72-year-old woman was admitted to the hospital because of dorsal, lumbar and lower abdomen pain that had started 4 days before. She had a history of age-related macular degeneration (treated with intraocular bevacizumab). Blood tests showed anaemia, thrombocytopaenia, acute kidney injury, elevated liver enzymes and total bilirubin (mainly because of the indirect fraction). Viral serologies and ADAMTS13 activity levels were normal, and stool testing was negative for Escherichia coli-producing Shiga toxins. E. coli was isolated in urine. Atypical haemolytic uremic syndrome triggered by a urinary tract infection or by the vascular endothelial growth factor-inhibitor bevacizumab were the most likely hypothesis. The patient started urgent plasmapheresis and dialysis that lasted for a total of 18 days. There was complete remission and recovery of kidney function allowing for treatment discontinuation, and she was discharged home. After 6 months of follow-up, she shows no signs of relapse. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  acute renal failure; dialysis; fluid electrolyte and acid-base disturbances; haematology (incl blood transfusion)

Mesh:

Substances:

Year:  2019        PMID: 31253663     DOI: 10.1136/bcr-2019-230026

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

Review 1.  Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option.

Authors:  Elena Román; Santiago Mendizábal; Isidro Jarque; Javier de la Rubia; Amparo Sempere; Enrique Morales; Manuel Praga; Ana Ávila; José Luis Górriz
Journal:  Nefrologia       Date:  2017 Sep - Oct       Impact factor: 2.033

2.  Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

Authors:  Fadi Fakhouri; Maryvonne Hourmant; Josep M Campistol; Spero R Cataland; Mario Espinosa; A Osama Gaber; Jan Menne; Enrico E Minetti; François Provôt; Eric Rondeau; Piero Ruggenenti; Laurent E Weekers; Masayo Ogawa; Camille L Bedrosian; Christophe M Legendre
Journal:  Am J Kidney Dis       Date:  2016-03-21       Impact factor: 8.860

3.  Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation.

Authors:  Takeshi Matsumoto; Xinping Fan; Eiji Ishikawa; Masaaki Ito; Keishirou Amano; Hidemi Toyoda; Yoshihiro Komada; Kohshi Ohishi; Naoyuki Katayama; Yoko Yoshida; Masanori Matsumoto; Yoshihiro Fujimura; Makoto Ikejiri; Hideo Wada; Toshiyuki Miyata
Journal:  Int J Hematol       Date:  2014-08-19       Impact factor: 2.490

4.  Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors.

Authors:  Gaëlle Pellé; Nasim Shweke; Jean-Paul Duong Van Huyen; Leïla Tricot; Sadika Hessaïne; Véronique Frémeaux-Bacchi; Christian Hiesse; Michel Delahousse
Journal:  Am J Kidney Dis       Date:  2011-02-04       Impact factor: 8.860

5.  An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Authors:  Josep M Campistol; Manuel Arias; Gema Ariceta; Miguel Blasco; Laura Espinosa; Mario Espinosa; Josep M Grinyó; Manuel Macía; Santiago Mendizábal; Manuel Praga; Elena Román; Roser Torra; Francisco Valdés; Ramón Vilalta; Santiago Rodríguez de Córdoba
Journal:  Nefrologia       Date:  2015-10-09       Impact factor: 2.033

6.  Rare Variants in the Functional Domains of Complement Factor H Are Associated With Age-Related Macular Degeneration.

Authors:  Michael P Triebwasser; Elisha D O Roberson; Yi Yu; Elizabeth C Schramm; Erin K Wagner; Soumya Raychaudhuri; Johanna M Seddon; John P Atkinson
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

7.  Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Authors:  Timothy H J Goodship; H Terence Cook; Fadi Fakhouri; Fernando C Fervenza; Véronique Frémeaux-Bacchi; David Kavanagh; Carla M Nester; Marina Noris; Matthew C Pickering; Santiago Rodríguez de Córdoba; Lubka T Roumenina; Sanjeev Sethi; Richard J H Smith
Journal:  Kidney Int       Date:  2016-12-16       Impact factor: 10.612

8.  Progressive bevacizumab-associated renal thrombotic microangiopathy.

Authors:  Alice L Uy; Novae B Simper; Anne L Champeaux; Robert M Perkins
Journal:  NDT Plus       Date:  2008-11-12

9.  Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.

Authors:  Hassan Izzedine; Bernard Escudier; Catherine Lhomme; Patricia Pautier; Philippe Rouvier; Victor Gueutin; Alain Baumelou; Lisa Derosa; Rastilav Bahleda; Antoine Hollebecque; Djillali Sahali; Jean Charles Soria
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

10.  Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing.

Authors:  Teresa Fidalgo; Patrícia Martinho; Catarina S Pinto; Ana C Oliveira; Ramon Salvado; Nina Borràs; Margarida Coucelo; Licínio Manco; Tabita Maia; M João Mendes; Rafael Del Orbe Barreto; Irene Corrales; Francisco Vidal; M Letícia Ribeiro
Journal:  Res Pract Thromb Haemost       Date:  2017-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.